Myths and mysteries about staging hepatic fibrosis by fibroscan
- PMID: 25451885
- PMCID: PMC4900149
- DOI: 10.1016/j.cgh.2014.10.030
Myths and mysteries about staging hepatic fibrosis by fibroscan
Conflict of interest statement
Comment on
-
Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases.Clin Gastroenterol Hepatol. 2015 Apr;13(4):763-71.e1-6. doi: 10.1016/j.cgh.2014.07.037. Epub 2014 Jul 30. Clin Gastroenterol Hepatol. 2015. PMID: 25086193
References
-
- Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1–3. - PubMed
-
- Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906. - PubMed
-
- Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–75. - PubMed
-
- Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
